Valtoco Spray
NDC Package 72252-520-04
Package Information
Valtoco (diazepam) sprays is a medication used to treat episodes of increased seizures (such as cluster or breakthrough seizures) in people who are already taking medications to control their seizures. This formulation utilizes a spray delivery system. Marketed by Neurelis, Inc, this product is identified by NDC 72252-520 and is authorized under FDA application NDA211635.
Identification & Billing
- RxCUI: 2272613 - diazePAM 10 MG in 0.1 mL Nasal Spray
- RxCUI: 2272613 - diazepam 100 MG/ML Nasal Spray
- RxCUI: 2272613 - diazepam 10 MG per 0.1 mL Nasal Spray
- RxCUI: 2272619 - VALTOCO 10 MG in 0.1 mL Nasal Spray
- RxCUI: 2272619 - diazepam 100 MG/ML Nasal Spray [Valtoco]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 72252 - Neurelis, Inc
- 72252-520 - Valtoco
- 72252-520-04 - 2 BLISTER PACK in 1 CARTON / 2 VIAL, SINGLE-DOSE in 1 BLISTER PACK / .1 mL in 1 VIAL, SINGLE-DOSE
- 72252-520 - Valtoco
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (72252-520). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 72252-520-04 identifies a specific commercial package of 2 blister pack in 1 carton / 2 vial, single-dose in 1 blister pack / .1 ml in 1 vial, single-dose of Valtoco, a human prescription drug labeled by Neurelis, Inc. This spray is formulated for nasal use and contains diazepam as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Neurelis, Inc on January 10, 2020. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
This medication is used to treat episodes of increased seizures (such as cluster or breakthrough seizures) in people who are already taking medications to control their seizures. This product is only recommended for short-term treatment of seizure attacks. It is not for ongoing daily use to prevent seizures. Uncontrolled seizures can turn into serious (possibly fatal) seizures that do not stop (status epilepticus). This medication is not recommended for children younger than 6 months of age because of the risk of serious side effects. Diazepam works by calming the brain and nerves. It belongs to a class of drugs known as benzodiazepines.
How is this Neurelis, Inc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 72252052004. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.
